Dr Najeed Aadil· @daakhsaab · X·· 2 days agoScore70
Body · original
MASTERPLAN (#ESMO26 , n=74): SBRT + chemotherapy vs chemotherapy alone:
🔹 Median OS: 22 vs 14 months
🔹 Median PFS: 11.9 vs 6.3 months
🔹 12-month locoregional recurrence: 20.2% vs 52%
Promising phase II results; confirmation needed.
#ESMO26
@OncoDailyGI
@larvo
174 views · 1 like · 1 repost · 0 replies
Conference abstracts
3136ROmatched by Rapid oral 1: Gastrointestinal tumour, upper digestive
Randomised phase II study of mFOLFIRINOX ± SBRT in patients with high risk, borderline resectable or locally advanced pancreatic cancer: Results of the AGITG MASTERPLAN trial
https://esmocongress.esmo.orgSource: Dr Najeed Aadil · x.com